Genetic Testing in Men With mCRPC

William Oh shared a post on LinkedIn about a recent paper by Pedro Barata et al. published in JAMA Oncology, commenting:

“How can we deliver precision medicine if we do not test for the presence of actionable mutations? In this RWD paper in JAMA Oncology by Pedro C Barata, MD MSc FACP and colleagues, <38% of CRPC patients had HRR (eg BRCA2) testing at all.

We know that up to 25% of these men may have germline or somatic mutations, and with multiple FDA-approved PARP inhibitors, many patients are not given a chance to receive life-prolonging therapy. Implementation of the care we already know works has to be a priority.”

“Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer”

Authors: Pedro C. Barata, Jonathan Assayag, Benjamin Li, Gordon Siu, Alexander Niyazov.

Source: William Oh/LinkedIn

William K. Oh is an American medical oncologist, academic, and industry leader, recognized for his expertise in managing genitourinary cancers, such as prostate, renal, bladder, and testicular cancers.

Oh serves as the Chief Medical Officer for the Prostate Cancer Foundation, the foremost philanthropic organization dedicated to prostate cancer.